Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Peter J. Watson et al.|JAMA|2017Cited by 891
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Anthony B. El-Khoueiry, Ignacio Melero et al.|Journal of Hepatology|2020Cited by 421
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical TrialBert H. O’Neil, Richard M. Goldberg, Monica M. Bertagnolli et al.|UNC Libraries|2020Cited by 96
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.Milind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|Journal of Clinical Oncology|2021Cited by 86